Enlivex traded to its all-time low of $0.42 per share on January 15, wiping out every retail investor who had ever bought the Nasdaq stock. The arthritis biotech, publicly listed for 12 years, had reinvented itself in November 2025 as what it called the "world's first prediction markets digital asset treasury." It raised over $200 million through a private placement, then spent the capital accumulating RAIN, a governance token of an Arbitrum-based prediction market protocol.
The company now holds approximately 78.8 billion RAIN tokens worth roughly $1.2 billion at current prices, representing 12% of the token's circulating supply. Even with RAIN having rallied substantially since last year, Enlivex shares have fallen 94% over the past five years and 30% year-to-date. Investors who bought at the $1 placement price have watched their stakes halve.
On-chain investigator ZachXBT flagged RAIN in May 2025, warning that the token provided "exit liquidity for insiders" and tied the project to a "sketchy DAT Enlivex." In follow-up reports, ZachXBT traced RAIN's funding to blockchain addresses that had previously moved money for TOMI and Data Ownership Protocol, two failed crypto projects. Moshe Hogeg, an Israeli entrepreneur currently under investigation by law enforcement for alleged $290 million in fraud, co-founded TOMI. Hogeg has denied the allegations through a spokesperson.
ZachXBT's analysis pointed to on-chain activity linking RAIN to blockchain addresses connected to Hogeg, though Hogeg's direct involvement in RAIN remains unclear from public disclosures. Enlivex appointed a former Italian prime minister to its board and marketed the token as "the Uniswap of prediction markets," but the company has not addressed the on-chain findings or the investigation into Hogeg.
The math that doesn't work
Enlivex's market capitalization sits at just $118 million, while its RAIN holdings carry a mark-to-market value of $1.2 billion. This gap signals either undisclosed encumbrances on the assets or fundamental problems with the company's solvency. Some RAIN is already pledged as collateral.
The token is thinly traded, meaning a large forced sale of Enlivex's holdings would likely fetch significantly less than the stated $1.2 billion. If the company faced a liquidity crisis or margin call on pledged collateral, the resulting dumping could crater RAIN's price and trap Enlivex shareholders in a cascading loss. The company's pivot into crypto assets that are difficult to liquidate has exposed shareholders to risks their own broker research may not have properly flagged.
Enlivex's trajectory mirrors a familiar pattern in retail crypto losses: a legitimate operating business repurposes itself as a treasury vehicle for a speculative token, concentrates shareholder capital in illiquid assets with insider connections, and leaves public shareholders as the bag holders when on-chain analysis surfaces structural problems. The company has not issued a statement responding to ZachXBT's research or the Hogeg investigation.